Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
2.
Revista Olhres ; 10(1):22, 2022.
Article in Portuguese | Web of Science | ID: covidwho-1777000

ABSTRACT

This study aimed to highlight how Piaget's theory can explain the writing learning evolution through the interaction between subject and object, from the point of view of reflecting ion. It was intended to make a relationship between the Psychogenesis of Written Language levels, elaborated by Emilia Ferreiro and Ana Teberosky, with the types of ions studied by Jean Piaget. The study aimed to show how the reflective ion is present when moving from an earlier, simpler level of writing to the next, more complex one. The data were collected through dialogues, inspired by the clinical method, with twelve children among 4- and 8-year-old of kindergarten and elementary school. The dialogues were conducted through digital platforms due to the absence of face-to-face classes caused by the Covid-19 pandemic. It was found that it is possible, due to the collected data, to make a connection with the reflecting ions, presented by the children, and the writing levels evidenced by the Psychogenesis of Written Language studies.

3.
Journal of the Neurological Sciences ; 429, 2021.
Article in English | EMBASE | ID: covidwho-1466683

ABSTRACT

Background and aims: Erenumab proved to be safe and well tolerated in a 5-year continuation of a 1-year double-blind, placebo-controlled study. Aim: to assess >48-week erenumab tolerability and safety in a real-world setting. Methods: In this long term (>48-week), multicenter (n = 15), longitudinal cohort real life study, we monitored all the adverse events emerged in consecutive adult patients with high-frequency episodic migraine (HFEM) or chronic migraine (CM) treated with monthly erenumab 70 mg or 140 mg from 20 December 2018 to 15 December 2020. Results: 442 patients (HFEM: 115;CM: 327) were treated with erenumab for >48 weeks: 209 (47.3%) patients were treated for 49–60 weeks, 132 (29.9%) for 61–72 weeks;73 (16.5%) for 73–84 weeks;21 (4.7%) for 85–100 weeks. Overall, >1 treatment emergent adverse event (TEAE) was reported by 136 (30.8%) [HFEM: 43 (37.4%);CM: 93 (28.4%)]. Most common TEAE were constipation (n = 66;14.9%), injection site erythema (n = 15;3.4%), and influenza (n = 7;1.6%). Serious adverse events (SAE) were reported by 8 patients (1.8%) and led to treatment discontinuation: severe constipation (n = 3), abdominal pain (n = 1), NSTEMI (n = 3), Covid-19 infection (n = 1). Only severe constipation was considered treatment-related SAE (0.45%). Conclusions: Conclusion: Erenumab is safe and well tolerated also in long-term treatment (>48 weeks) in real life.

SELECTION OF CITATIONS
SEARCH DETAIL